Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) jumped 12.18% to reach at $4.88 during previous trading session. The company has experienced volume of 2,396,900 shares while on average the company has a capacity of trading 1.55M share.
Anavex Life Sciences Corp. (NASDAQ:AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, on December 12, 2016 reported financial results for its fiscal year ended September 30, 2016.
Cash and cash equivalents of $17.3 million as of December 12, 2016, and $9.2 million at September 30, 2016, compared to $15.3 million at September 30, 2015.
During fiscal year 2016, Anavex used $9.2 million in cash to fund operations, which was within the Company’s spending plan guidance.
Operating expenses for the year ended September 30, 2016, were $15.6 million, which included $5.1 million non-cash charges, compared to $7.1 million for the comparable period in fiscal year 2015. The increase was primarily attributable to ongoing clinical trial activities, preclinical work, and expansion of the Company’s team.
Net loss for fiscal year 2016 was $14.7 million, or $0.42 per share, compared to a net loss of $12.1 million, or $0.65 per share, for the 2015 fiscal year.
Anavex Life Sciences Corp. (NASDAQ:AVXL) holds the market capitalization of $155.34M along with 35.71M outstanding shares. During the last trade, stock’s minimum price has been reached out at $4.43 while the maximum trading price moved at $4.88. Currently the stock price is moving -41.20% off from the highest level of twelve months and +100.82% above from twelve months low. Anavex Life Sciences Corp. (NASDAQ:AVXL) marked 52-week highest price level of $8.30 on 07/11/16 and 52-week lowest price level of $2.43 on 09/21/16. For the stock, price target value has been calculated at $15.00 based on calls of 1 experts. Stock’s minimum price target estimates has been figured out at $15.00 while the maximum price target forecast is established at $15.00.
As of current trade, Anavex Life Sciences Corp. (NASDAQ:AVXL) has shown weekly upbeat performance of 28.42%. Its six months performance indicated a bullish movement while its yearly performance reflected a negative trend of -31.36%. Year-to-date (YTD) performance of the stock illustrate upbeat downbeat trend of -12.39%. Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) currently have an ABR of 1.00, derived from a total of 2 opinions. The company’s price sits 43.43% above from its 50-day moving average of $3.44 and 14.16% above from the stock’s 200-day moving average of $3.97. The company has Relative Strength Index (RSI 14) of 78.17 along with Average True Range (ATR 14) of 0.30. Its weekly and monthly volatility is 8.97%, 7.90% respectively. The company’s beta value is at -0.05.
Anavex Life Sciences Corp. (NASDAQ:AVXL) price to book ratio for most recent quarter is 23.24, whereas price to cash per share for the most recent quarter is 17.48. Anavex Life Sciences Corp. (NASDAQ:AVXL)’s quick ratio for most recent quarter is 4.50 along with current ratio for most recent quarter of 4.50. Total debt to equity ratio of the company for most recent quarter is 0.01 whereas long term debt to equity ratio for most recent quarter is 0.00. Anavex Life Sciences Corp. (NASDAQ:AVXL) has a Return on Assets of -105.60%. The company currently has a Return on Equity of -130.40%.